Stocksigma LogoStocksigma Logo

Vista Pharma Q3FY26: Revenue Declines and Net Loss Widens

Vista Pharmaceuticals reported a widened Net Loss of Rs 231.94 lakhs for the quarter ended 31 Dec'25, compared to a loss of Rs 132.23 lakhs YoY

Vista Pharma Q3FY26: Revenue Declines and Net Loss Widens

Vista Pharmaceuticals Ltd 路 Outcome 路 13 Feb 2026, 8:56 pm

Vista Pharma Q3FY26: Revenue Declines and Net Loss Widens Vista Pharmaceuticals reported a widened Net Loss of Rs 231.94 lakhs for the quarter ended 31 Dec'25, compared to a loss of Rs 132.23 lakhs YoY. Revenue from operations declined 5.4% YoY to Rs 241.82 lakhs. The loss before tax increased to Rs 328.04 lakhs from Rs 180.44 lakhs YoY, impacted by higher expenses. Notably, the company recognized an Expected Credit Loss provision of Rs 205.43 lakhs against long-pending trade receivables. Basic EPS for the quarter stood at Rs (0.41).

Original exchange filing (PDF)

More announcements from Vista Pharmaceuticals Ltd

All Vista Pharmaceuticals Ltd announcements